pt141+ PT-141-Nasal Spray EllieMD | PT-141 Injection
Description
64 Thirty-eight patients were randomized to receive either setmelanotide 3 mg subcutaneous injection daily (n=19) or placebo (16 patients with BBS and 3 with AS in each group) during the 14-week double-blind period, followed by open-l abel setmelanotide for 52 weeks
Less yellow keeps it in the red-brown zone
PMID 19346257
Communications Cutaneous Melanotic Schwannoma in a Pediatric Patient Quoc-Bao D
Synchronize peptide dosing with ovulation tracking: start protocols in the luteal or follicular phase based on the peptides mechanism
